<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02549937</url>
  </required_header>
  <id_info>
    <org_study_id>2015-012-00US1</org_study_id>
    <nct_id>NCT02549937</nct_id>
  </id_info>
  <brief_title>A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective Dose Escalation:&#xD;
&#xD;
      To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors&#xD;
      and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).&#xD;
&#xD;
      Primary Objective Dose Expansion:&#xD;
&#xD;
      To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract&#xD;
      Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with&#xD;
      locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs),&#xD;
      and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with&#xD;
      advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients&#xD;
      with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, dose escalation and expansion clinical trial of surufatinib&#xD;
      orally once daily (QD) in patients with advanced solid tumors.&#xD;
&#xD;
      The study consists of two phases:&#xD;
&#xD;
      Dose escalation phase - A 3+3 design will be used for this portion of the study.&#xD;
&#xD;
        -  Approximately 15 to 35 evaluable patients will be enrolled. The actual number of&#xD;
           patients depends on the Dose-limiting toxicity (DLT) situation as well as the RP2D dose&#xD;
           level reached in this trial.&#xD;
&#xD;
        -  The trial will approximately evaluate five surufatinib dose levels at 50,100, 200, 300&#xD;
           and 400 mg/day.&#xD;
&#xD;
      Expansion phase:&#xD;
&#xD;
      Approximately 105 patients will be enrolled into one of four open-label treatment arms during&#xD;
      this phase: at least 30 patients with advanced BTC that has progressed on standard ﬁrst-line&#xD;
      chemotherapy will be assigned to Arm A, at least 15 patients with advanced pNET that has&#xD;
      progressed on either everolimus, sunitinib, or both will be assigned to Arm B, at least 15&#xD;
      patients with advanced EP-NET that has progressed on everolimus will be assigned to Arm C,&#xD;
      and at least 45 patients with Soft Tissue Sarcoma will be assigned to Arm D. Subjects&#xD;
      enrolled in this phase are to be evaluated for the safety, tolerability and pharmacokinetic&#xD;
      (PK) characteristics to confirm the selected surufatinib dose.&#xD;
&#xD;
      Subjects will receive surufatinib daily treatment continuously with every 28-day treatment&#xD;
      cycle until disease progression, death, or intolerable toxicity at the investigator's&#xD;
      discretion for a favorable benefit to risk balance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of DLT</measure>
    <time_frame>From date of enrollment through end of Cycle 1, up to 28 days</time_frame>
    <description>The primary outcome during dose escalation will be the incidence rate of DLTs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) rate</measure>
    <time_frame>From date of enrollment to progression or death up to 18 months</time_frame>
    <description>The primary outcome during dose expansion will be the PFS rate for each cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration calculated with Blood samples</measure>
    <time_frame>within 30 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum concentration calculated with Blood samples</measure>
    <time_frame>within 30 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>within 30 days after the last dose</time_frame>
    <description>the proportion of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>Escalation 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort at 50 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort at 100 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort at 200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort at 300 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation cohort at 400 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>surufatinib</intervention_name>
    <description>orally once daily (QD) in patients with advanced solid tumor.</description>
    <arm_group_label>Escalation 100mg</arm_group_label>
    <arm_group_label>Escalation 200 mg</arm_group_label>
    <arm_group_label>Escalation 300 mg</arm_group_label>
    <arm_group_label>Escalation 400 mg</arm_group_label>
    <arm_group_label>Escalation 50 mg</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
    <other_name>HMPL-012</other_name>
    <other_name>sulfatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Fully understand the study and voluntarily sign the informed consent form;&#xD;
&#xD;
          -  At least 18 years old;&#xD;
&#xD;
          -  Histologically or cytologically documented, locally advanced or metastatic solid&#xD;
             malignancy of any type during the dose escalation phase, that has progressed on&#xD;
             available standard systemic therapy, and for whom no effective therapy or standard of&#xD;
             care exists; and locally advanced or metastatic BTC that has progressed on standard&#xD;
             ﬁrst-line chemotherapy; locally advanced or metastatic pNET that has progressed on&#xD;
             everolimus, sunitinib or both; locally advanced or metastatic EP-NET that has&#xD;
             progressed on everolimus; advanced STS that has progressed on at least one line of&#xD;
             standard therapy or refused standard frontline cytotoxic chemotherapy during the&#xD;
             expansion phase;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypertension that is not controlled by antihypertension medication, defined as:&#xD;
             systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg;&#xD;
&#xD;
          -  History or presence of digestive tract diseases, including active gastric/duodenal&#xD;
             ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal&#xD;
             tumor, or an evaluation by investigators of having any other condition that could&#xD;
             possibly result in gastrointestinal tract hemorrhage or perforation;&#xD;
&#xD;
          -  History or presence of serious hemorrhage , hemoptysis or hematemesis within 3 months&#xD;
             or a thromboembolic event (including Deep Vein Thrombosis (DVT), stroke and/or&#xD;
             transient ischemic attack) within 6 months;&#xD;
&#xD;
          -  Patients with squamous Non Small Cell Lung Cancer (NSCLC) should be excluded;&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, including but not limited to, acute&#xD;
             myocardial infarction within 6 months prior to enrollment, severe/unstable angina&#xD;
             pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV&#xD;
             congestive heart failure, ventricular arrhythmias requiring treatment or left&#xD;
             ventricular ejection fraction (LVEF) &lt; 50%;&#xD;
&#xD;
          -  Systemic anti-neoplastic therapies within 4 weeks prior to the initiation of&#xD;
             investigational treatment, including chemotherapy, radical radiotherapy,&#xD;
             hormonotherapy, biotherapy and immunotherapy;&#xD;
&#xD;
          -  Palliative radiotherapy for bone metastasis/lesion within 2 weeks;&#xD;
&#xD;
          -  Known Human immunodeficiency virus (HIV) infection;&#xD;
&#xD;
          -  Known clinically significant history of liver disease, including viral or other&#xD;
             hepatitis, current alcohol abuse, or cirrhosis;&#xD;
&#xD;
          -  Women who are pregnant or lactating;&#xD;
&#xD;
          -  Brain metastases and/or spinal cord compression untreated with surgery and/or&#xD;
             radiotherapy, and without clinical imaging evidence of stable disease for 14 days or&#xD;
             longer; Subjects requiring steroids within 4 weeks prior to start of study treatment&#xD;
             will be excluded;&#xD;
&#xD;
          -  Inability to take medication orally, dysphagia or an active gastric ulcer resulting&#xD;
             from previous surgery or a severe gastrointestinal disease, or any other condition&#xD;
             that investigators believe may affect absorption of the investigational product;&#xD;
&#xD;
          -  Received investigational treatment in another clinical study within 4 weeks prior to&#xD;
             the initiation of investigational treatment;&#xD;
&#xD;
          -  Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory&#xD;
             result, or any other condition that investigators suspect may prohibit use of the&#xD;
             investigational product, affect interpretation of study results, or put the patient at&#xD;
             high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Kauh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison MediPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Ford</last_name>
    <email>Jenniferf@hmplglobal.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daneng Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Cohn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SCRI at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Falchook, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Sung, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sujana Moova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hamilton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Strauss, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Paulson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arvind Dasari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Maserati</last_name>
      <phone>+390223902182</phone>
    </contact>
    <contact_backup>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <phone>+390223902182</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>September 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2015</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biliary</keyword>
  <keyword>pancreatic</keyword>
  <keyword>neuroendocrine</keyword>
  <keyword>carcinoid</keyword>
  <keyword>PNET</keyword>
  <keyword>EP-NET</keyword>
  <keyword>extrapancreatic</keyword>
  <keyword>sarcoma</keyword>
  <keyword>soft tissue sarcoma</keyword>
  <keyword>STS</keyword>
  <keyword>BTC</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

